Podcast #58 · 5 May 2026
Advanced Hepatocellular Carcinoma: Navigating Second-Line Therapy Options
- Tyrosine Kinase Inhibitor (TKI)
- Medical Oncology
- Gastroenterology
- Liver Cancer
- Immunotherapy
- Hepatocellular Carcinoma (HCC)
- Biomarkers
- Next-Generation Sequencing (NGS)
- Hepatology
- 2026 HCC Creator Weekend™
When first-line treatment for advanced hepatocellular carcinoma (HCC) fails and the disease progresses, what options are available for second-line therapy? In this episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi explore the uncertain landscape of second-line treatment after first-line immunotherapy, such as atezolizumab and bevacizumab or the STRIDE regimen, including practical considerations for choosing which second-line therapy to use.